The treatment of anal cancer in patients who are seropositive for HIV (HIV-positive) has been controversial for more than 3 decades. Current treatment guidelines recommend that healthy HIV-positive patients receive standard fluorouracil and mitomycin C concurrent chemoradiotherapy, but some investigators question whether these patients experience more severe toxic effects or worse long-term outcomes that might necessitate a modified treatment approach. This study investigates the influence of HIV status on patient outcomes in a national cohort of US veterans.
]; P < .001). There were no differences in tumor/ node stage, comorbidity, chemotherapy regimen, or radiation dose. Among HIV-positive patients, the median pretreatment CD4 lymphocyte count was 370/μL (interquartile range, 205-543/μL) (to convert to cells ×10 9 /L, multiply by 0.001), and 91% of patients had received highly active antiretroviral therapy (HAART) in the 6 months before cancer treatment.
Patients with HIV were as likely as HIV-negative patients to miss a second cycle of any chemotherapy (odds ratio [OR], 1.38; 95% CI, 0.77-2.47; P = .27), but were more likely to miss We demonstrate that patients with HIV have a higher risk than HIV-negative patients for acute treatment-related toxic effects, especially hematologic toxic effects. However, this finding does not translate to inferior long-term outcomes, and HIVpositive patients showed survival and ostomy placement rates equivalent to those of their HIV-negative counterparts. These data point to the need to optimize treatment in this population to decrease or better manage acute toxic effects. Our results also paint an optimistic picture of the long-term prognosis for HIV-positive patients, reflecting the improvements in HIV disease control and supportive care for this vulnerable population. 4 The program is a coordinated registry of all patients with cancer in participating areas in the United States, covering 28% of the population and representative of national demographics. Our sample included adults aged 19 to 64 years with a first-time cancer diagnosis. Indiana University's institutional review board deemed this study to be nonhuman subjects research that did not require their approval or patient informed consent. The outcome was the percentage of adults uninsured at diagnosis. We analyzed unadjusted changes in 2014, when the ACA health insurance exchanges and Medicaid expansion went into effect, compared with pre-ACA years 2010-2013. We repeated this analysis stratifying by (1) tumor location for the 5 most common types of nonskin cancer, (2) cancer stage, (3) race/ ethnicity, and (4) county poverty rate. We used difference-indifferences regression to assess whether changes in coverage were greater in states with Medicaid expansion than in nonexpansion states, with robust SEs clustered at the state level and adjusting for patient and county characteristics. All analysis was conducted using Stata software, version 14 (StataCorp). P values are 2-sided, and P < .05 indicates statistical significance.
Results | Data were obtained from the SEER Program for 858 193 nonelderly adults with new cancer diagnoses. Of these, 468 131 (54.55%) were women, and the mean (SD) age was 52.44 (9.66) years. The Limitations of our analysis include the availability of data from 13 states and 1 year of post-ACA data. Our results are descriptive, and our quasi-experimental Medicaid analysis is subject to potential time-varying confounders. Furthermore, other research indicates that uninsured patients are less likely to be diagnosed with cancer and more likely to be diagnosed at late stages.
3 Our finding that uninsurance was greater among those with distant disease in the pre-ACA and post-ACA periods is in line with research suggesting that uninsured patients may not seek care until their cancer has progressed. Although we provide novel evidence that fewer patients newly diagnosed with cancer were uninsured in the post-ACA period, our analysis did not separate the effects of gains in coverage among patients who would have been diagnosed in the absence of the ACA from changes in the number of diagnoses resulting from increased coverage. Future research should examine effects of coverage on cancer diagnoses, treatment, and outcomes. Policy changes that reduce Medicaid funding or weaken protections for individuals with preexisting conditions could be particularly harmful for patients with cancer.
